Cell Therapy Manufacturing Market Expected to Achieve US$ 15.6 Billion by 2033 at an Astonishing 14.2% CAGR, According to FMI

The global cell therapy manufacturing market is on the brink of substantial expansion, with a projected value of US$ 4,134.48 million in 2023. This dynamic market is expected to sustain an impressive compound annual growth rate (CAGR) of 14.2% from 2023 to 2033, ultimately culminating in an estimated worth of around US$ 15,634.67 million by the conclusion of 2033. Notably, in 2021, autologous cell therapy manufacturing led the global market with a commanding share of approximately 56.0%.

Cell therapies find widespread application in the treatment of viral infections, cancer, hemoglobinopathies, and hereditary immunological disorders. The advent of reagents and closed-system automated equipment for cellular therapy production is a direct outcome of the escalating research activities in this field.

A decentralized manufacturing model for clinical trials in cell therapies, encompassing multiple sites, is gaining favor on a global scale. Such approaches advocate patient treatment using cells produced by automated equipment at each participating center, all under the umbrella of a single, centrally managed investigational new drug application (IND).

Click Here to Access Your Visuals-Packed Report!
https://www.futuremarketinsights.com/reports/sample/rep-gb-15536

Many academic centers are nowadays investing in the development of such automated devices for point-of-care manufacturing and engagement in decentralized multi-center Clinical Trials. The global cell therapy manufacturing market would thus observe a boom in the next decade. Besides, the introduction of novel therapies licensed by regulatory bodies for targeted therapeutic approaches would further propel the overall growth in the market during the projected period.

Key Takeaways from the Market Study

• By source, the autologous segment held a global market share of about 0% in 2021.
• Based on indication, the cancer segment held nearly 0% in 2021 in the cell therapy manufacturing market.
• In terms of purpose, the clinical segment accounted for around 0% of the global market share in 2021.
• The injectable route of administration of cell therapies generated a global market share of around 0% in 2021.
• By cell type, the hematopoietic stem cells (HSC) segment held a share of around 0% in the global cell therapy manufacturing market in 2021.
• By end use, the hospital settings category generated a share of around 1% in 2021 in the global cell therapy manufacturing market.
• China held a share of around 2% in 2021 in the East Asia cell therapy manufacturing market.

“Increasing number of research activities by key companies to reduce risks and get ready for a highly productive future are anticipated to drive the market. Besides, they are striving to develop innovative technologies that can assist investigators in automating their processes for gaining success in future,” says an analyst of Future Market Insights.

Competitive Landscape: Cell Therapy Manufacturing Market

Key players in the cell therapy manufacturing market are focusing on R&D activities to initiate regenerative medicine manufacturing. Moreover, they are promoting commercial manufacturing for their clients by offering novel solutions to cell therapy developers.

For instance,

• In March 2022, Thermo Fisher Scientific presented a new large-volume electroporation system, the purpose of which is to simplify cell therapy development. The company aims to simplify the transition from clinical development to commercial manufacturing among Cell Therapy Developers.
• Charles River Laboratories’ Memphis plant became the first CDMO in North America to manufacture commercial allogeneic cell therapies after receiving European Medicines Agency (EMA) approval in August 2022.

Click Here to Request Methodology!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-15536

Get Exclusive Insights on the Cell Therapy Manufacturing Market

Future Market Insights offers a unique perspective and actionable insights on the cell therapy manufacturing market in its latest study, presenting a historical demand assessment of 2012 – 2021 and projections for 2022 – 2032. The global cell therapy manufacturing market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Key Players:

1. Merck KGaA
2. Avantor, Inc.
3. Cell Therapies Pty Ltd
4. Thermo Fisher Scientific
5. Charles River Laboratories
6. Catalent, Inc
7. Bio-Techne
8. Cytiva
9. Lonza
10. The Discovery Labs
11. BIOCENTRIQ
12. FUJIFILM Diosynth Biotechnologies
13. Novartis AG
14. Bristol-Myers Squibb Company
15. Gilead Sciences, Inc.
16. WuXi AppTec.
17. OXGENE
18. Pharmaron
19. Aldevron
20. FLODESIGN SONICS
21. Exothera

Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/15536

Key Segments Covered in the Cell Therapy Manufacturing Industry

By Source:

• Autologous
• Allogenic

By Indication:

• HIV
• Autoimmune Disorders
• Immune Deficiencies
• Cancer
• Neurological Disorders

By Manufacturing Purpose:

• Clinical
• Commercial
• Pre-clinical

By Route of Administration:

• Topical
• Injectable
• Infusion
• Implantable Bio-Scaffold

By Cell Type:

• Hematopoietic (Blood-Forming) Stem Cells (HSC)
• Skeletal Muscle Stem Cells
• Mesenchymal Stem Cells
• Lymphocytes
• Dendritic Cells
• Pancreatic Islet Cells
• CAR-T Cells

By End User:

• Hospital Settings
• Intensive Outpatient Treatment Centers
• Academic and Research Institutes
• Specialty Clinics

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube